| Identification | Back Directory | [Name]
Benzeneacetic acid, α-cyclopentyl-4-(2-quinolinylmethoxy)-, (αS)- | [CAS]
128253-32-7 | [Synonyms]
Benzeneacetic acid, α-cyclopentyl-4-(2-quinolinylmethoxy)-, (αS)- | [Molecular Formula]
C23H23NO3 | [MOL File]
128253-32-7.mol | [Molecular Weight]
361.43 |
| Chemical Properties | Back Directory | [Boiling point ]
555.4±40.0 °C(Predicted) | [density ]
1.242±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
4.47±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
(S)-Veliflapon ((S)-BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC50 values of 0.026 μM, 0.039 μM and 0.22 μM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood[1][2][3]. | [References]
[1] Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95. DOI:10.1007/BF01976210
[2] Hermann, David J., et al. Dosing schedules of leukotriene synthesis inhibitors for human therapy. World Intellectual Property Organization. WO2009002746.
[3] Helgadottir, et al. Polymorphisms in the susceptibility genes for myocardial infarction, stroke, and peripheral artery occlusive disease and their use in risk assessment and prophylaxis therapy. United States. US20070280917. |
|
|